Location History:
- Fitzroy, AU (2009)
- North Fitzroy, AU (2014)
Company Filing History:
Years Active: 2009-2014
Title: Innovations of David Ching Siang Huang in Apoptosis Modulation
Introduction
David Ching Siang Huang, an esteemed inventor based in North Fitzroy, Australia, has made significant contributions to the field of medical research, particularly in the modulation of apoptosis. With two patents to his name, Huang's work focuses on developing therapeutic agents aimed at inducing cell death in specific target populations, such as cancer cells.
Latest Patents
Huang’s most recent patents include:
1. **Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same**: This invention involves therapeutic molecules designed to modulate apoptosis in target cells. The agents inhibit pro-survival molecules and promote apoptosis in cancer cells. Furthermore, it provides methodologies for generating and selecting these therapeutic agents and pharmaceutical compositions that utilize them.
2. **Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis**: This patent introduces novel molecules that influence apoptosis in mammalian cells. It focuses on a newly identified member of the Bcl-2 family of proteins, known as 'Bmf', and includes genetic sequences that encode these proteins. The invention highlights the potential of Bmf as a BH3-only molecule that interacts with pro-survival Bcl-2 family members, thereby triggering apoptosis. The research also encompasses genetically modified animals, which can serve as models for screening therapeutic agents aimed at conditions related to apoptotic defects.
Career Highlights
David Ching Siang Huang is affiliated with the Walter and Eliza Hall Institute of Medical Research, where he has been instrumental in advancing research on apoptosis. His innovative work continues to pave the way for novel therapies in oncology and related fields.
Collaborations
Huang collaborates closely with notable researchers such as Andreas Strasser and Hamsa Puthalakath. Their joint efforts contribute to a deeper understanding of apoptosis and the development of effective therapeutic strategies against diseases characterized by malfunctioning apoptotic processes.
Conclusion
David Ching Siang Huang exemplifies the innovative spirit in medical research, particularly through his patents that address critical mechanisms of cell death. His contributions not only enhance our understanding of apoptosis but also hold promise for developing targeted therapies to combat cancer and other diseases.